Log in to search using one of your social media accounts:

 

Targeting a microRNA shows potential to enhance effectiveness of diabetes drugs
(University of Alabama at Birmingham) Researchers have found a vital role for miR-204 in beta cells -- regulating the cell surface receptor that is the target of many of the newer type 2 diabetes drugs, such as Byetta, Victoza, Trulicity, Januvia, Onglyza and Tradjenta. This drug target is the glucagon-like peptide 1 receptor, or GLP1R. Activation of GLP1R with these drugs helps the beta cell produce and secrete more insulin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2017 Category: International Medicine & Public Health Source Type: news

Ertugliflozin: Promise From Yet Another SGLT-2 Inhibitor (CME/CE)
(MedPage Today) -- Assessed as triple agent therapy when added to metformin, sitagliptin (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 25, 2017 Category: Cardiology Source Type: news

Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials
In two phase 3 trials, the SGLT2 inhibitor ertugliflozin for the treatment of type 2 diabetes that is uncontrolled with metformin alone or with sitagliptin demonstrated safety and efficacy at 52 weeks.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

More people treated with once-weekly semaglutide achieved reductions in both glucose and weight vs. comparator treatments
A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER). (Source: World Pharma News)
Source: World Pharma News - September 12, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Janumet (Sitagliptin Metformin HCL) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 28, 2017 Category: Drugs & Pharmacology Source Type: news

Juvisync (Sitagliptin and Simvastatin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 21, 2017 Category: Drugs & Pharmacology Source Type: news

Fewer T2D Patients Advanced Therapy With GLP-1 Pump
(MedPage Today) -- Less need for additional drugs with implantable exenatide versus sitagliptin, placebo (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 12, 2017 Category: Primary Care Source Type: news

Why Did the FDA Refuse to Add TECOS Data to Sitagliptin Label? Why Did the FDA Refuse to Add TECOS Data to Sitagliptin Label?
Although it's not clear exactly what Merck was requesting when it asked the FDA to add the TECOS data to the label for its type 2 diabetes drug, the recent refusal of the agency to do so is mystifying.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Merck to Present New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA ® (sitagliptin), and Real-World Evidence Research at the 77th Scientific Sessions of the American Diabetes Association
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that 19 scientific presentations from Merck ’s diabetes pipeline and portfolio – including Phase 3 data for investigational ertugliflozin, additional analyses of JANUVIA® (sitagliptin), and real-world research – will be presented at the 77th Scientific Sessions of the American Diabetes Association (ADA) in San Diego, June 9-13, 2017.Language: EnglishContact: MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-740-6179orInve...
Source: Merck.com - Product News - May 16, 2017 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news

TECOS: Sitagliptin Safe in CKD Patients (CME/CE)
(MedPage Today) -- Sub-analysis in patients with chronic kidney disease and T2DM raised no safety concerns (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 26, 2017 Category: Cardiology Source Type: news

FDA Turns Down Sitagliptin Heart Data for Drug Label
(MedPage Today) -- TECOS results apparently not good enough to warrant new claim (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 7, 2017 Category: Urology & Nephrology Source Type: news

Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Dateline City: KENILWORTH, N.J.KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck ’s Supplemental New Drug Applications for JANUVIA®(sitagliptin), JANUMET® (sitagliptin and metformin HCl) and JANUMET XR® (sitagliptin and metformin HCl extended-release).Language: EnglishContact: MerckMedia:Pamela Eisele, 267-305-3558orKristen Drake, 908-236-4223orInvestors:Amy Klug, 908-740-1898Ticker Slug:Ticker:MRKExchange:NY...
Source: Merck.com - Corporate News - April 7, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Source Type: news

Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment
Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin, exenatide extended release (ER) and insulin glargine U100 in adults with type 2 diabetes, across multiple background oral antidiabetic (OAD) treatment categories. (Source: World Pharma News)
Source: World Pharma News - April 3, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes
Dateline City: KENILWORTH, N.J.& NEW YORK Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA® (sitagliptin) or MetforminKENILWORTH, N.J.& NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S.Language: EnglishContact: Merck Media:Doris Li, (908) 246-5701orMerck Investor:Amy Klug, (908) 740-1898orKristen Drake, (908) 236-4223orPfizer Media:Steve Danehy, (212) 733-1538orPfizer Investor:Ryan Crowe, (212) 733-8160Ticker Slug:Ticker:MRKExchange:NYSET...
Source: Merck.com - Research and Development News - March 6, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK #Pfizer $MRK $PFE Januvia MSD NYSE:MRK Source Type: news

Study Finds No Safety Concerns for Sitagliptin Use in Elderly Study Finds No Safety Concerns for Sitagliptin Use in Elderly
Sitagliptin does not appear to increase the risk of cardiovascular events in patients with type 2 diabetes who are 75 years or older, according to results from the TECOS trial. (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 3, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Janumet XR (Sitagliptin and Metformin HCl) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 31, 2017 Category: Drugs & Pharmacology Source Type: news

Sitagliptin Insulin Evaluated in Hospitalized T2D Patients (CME/CE)
(MedPage Today) -- Combination proved non-inferior to standard basal-bolus insulin treatment (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - December 15, 2016 Category: Consumer Health News Source Type: news

The Year In Review: Merck Can Look Back And Smile
Merck has had a reasonably good year. The company saw a turn-around in its business on the back of its relatively new cancer drug, Keytruda. The anti-infectives division sustained itself, with key metabolism drugs Januvia and Janumet gradually inching up. In fact, the competitive pressure from J&J ’s Invokana, which threatened [...] (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 13, 2016 Category: Pharmaceuticals Authors: Trefis Team, Contributor Tags: NYSE:MRK Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Mixed Findings on Renal Outcomes With DPP-4 Inhibitors in T2D Mixed Findings on Renal Outcomes With DPP-4 Inhibitors in T2D
Renal outcomes data from two large cardiovascular-outcomes trials with the type 2 diabetes drugs saxagliptin and sitagliptin, both DPP-4 inhibitors, hint at some kidney benefit with saxagliptin.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 4, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

EASD: Novel SGLT2 Drug Works in Triple Therapy (CME/CE)
(MedPage Today) -- Ertugliflozin improved T2D control atop metformin/sitagliptin (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 15, 2016 Category: Urology & Nephrology Source Type: news

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes
Dateline City: KENILWORTH, N.J., and NEW YORK, N.Y.New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting – Study Achieved Primary and All Key Secondary EndpointsKENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint.Language: Englishread more (Source: Merck.com - Research and Development News)
Source: Merck.com - Research and Development News - September 15, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Switching GLP-1 For DPP-4 Improves Net T2D Outcomes
(MedPage Today) -- Victoza bests Januvia for combo therapy on A1c, weight, hypoglycemia composite (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 13, 2016 Category: Cardiology Source Type: news

Januvia (Sitagliptin Phosphate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 8, 2016 Category: Drugs & Pharmacology Source Type: news

Merck Results Underscore Need To Go Big Or Go Home In Diabetes Market
Looking at the earnings posted by Merck & amp; Co. (MRK), I could not help but compare and contrast them with what Sanofi (SNY) said this morning. Like Sanofi had with Lantus, Merck has a mega-blockbuster with Januvia. Just as Lantus was getting long in the tooth and facing patent expiration so too is Januvia. The main difference is how each company planned for life beyond their respective mega-blockbusters. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 29, 2016 Category: Pharmaceuticals Authors: David Kliff Source Type: news

Sitagliptin anti-atherosclerotic effects may be inconsequential
Results of the PROLOGUE study show that the dipeptidyl peptidase-4 inhibitor sitagliptin has no greater effect than other antidiabetic medications on progression of carotid intima-media thickness. (Source: MedWire News)
Source: MedWire News - June 30, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news

Harnessing The Gut-Brain Axis
Nancy Thornberry is the CEO of Kallyope. . Nancy was formerly Senior Vice President and Franchise Head, Diabetes and Endocrinology, Merck & Co. Inc. In this role she led discovery and clinical research in diabetes, osteoporosis, fertility and contraception. Prior to her role as Franchise Head, Nancy initiated and was a leader of Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery of JANUVIA® for the treatment of Type 2 diabetes. Among other notable scientific accomplishments is the identification of the first caspase, interleukin-1β converting enzyme (ICE/caspase-1). For her s...
Source: Forbes.com Healthcare News - June 28, 2016 Category: Pharmaceuticals Authors: Josh Wolfe Source Type: news

FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain
[8-28-2015] The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines sitagliptin, saxagliptin, linagliptin, and alogliptin may cause joint pain that can be severe and disabling. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 23, 2016 Category: Drugs & Pharmacology Source Type: news

Think Twice Before Prescribing DPP-4 Inhibitors for DiabetesThink Twice Before Prescribing DPP-4 Inhibitors for Diabetes
In this commentary, the author raises thought-provoking questions regarding the potential risks and benefits of using sitagliptin in high-risk patients with inadequately controlled type 2 diabetes. Evidence-Based Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Subdermal mini-pump with exenatide superior to sitagliptin in reducing HbA1c
NEW ORLEANS – The second trial involving a sub-dermal matchstick-size osmotic mini-pump that releases exenatide over 6 months in people who have poorly controlled type 2 diabetes achieved superior... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 12, 2016 Category: Endocrinology Source Type: news

Meet The Woman Who Launched A New Field Of Scientific Study
As a female chemical engineer, Frances Arnold was already a rarity. After all, only about 16 percent of chemical engineers are women. But now that she has become the first woman ever to win the prestigious Millennium Technology Prize — it was awarded in Helsinki, Finland, on May 24 — Arnold is truly one of a kind. And she knows that in addition to a big cash award (1 million euros, or about $1.3 million), the prize brings an opportunity to spotlight the gender gap in STEM (science, technology, engineering and math) careers and to be a role model for other women. "I hope that my getting this prize will high...
Source: Science - The Huffington Post - May 31, 2016 Category: Science Source Type: news

Sitagliptin No Help for Fatty Liver
(MedPage Today) -- But study supports use of MRI as non-invasive liver fat measure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 17, 2016 Category: Cardiology Source Type: news

Diabetes drug found no better than placebo at treating nonalcoholic fatty liver disease
A randomised, double-blind, controlled trial of sitagliptin showed that the diabetes medication works no better than a pacebo in treating nonalcoholic fatty liver disease. Science Daily (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 16, 2016 Category: Endocrinology Source Type: news

Diabetes drug, placebo work the same on fatty liver disease
Stephen FellerSAN DIEGO, May 12 (UPI) -- The diabetes drug Januvia was shown in a recent study to have the same effect as placebo against non-alcoholic fatty liver disease, researchers report. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 12, 2016 Category: Consumer Health News Source Type: news

Diabetes drug found no better than placebo at treating nonalcoholic fatty liver disease
A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed under the name Januvia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 12, 2016 Category: Science Source Type: news

Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association
Dateline City: KENILWORTH, N.J. Additional Analyses from the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Also to Be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present data from clinical trials of its investigational diabetes pipeline, JANUVIA® (sitagliptin), and new real-world research in more than 20 scientific data presentations at the 76th Scientific Sessions of the American Diabetes Association (...
Source: Merck.com - Corporate News - May 12, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ADA Source Type: news

Diabetes drug found no better than placebo at treating NAFLD
A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia. (Source: World Pharma News)
Source: World Pharma News - May 12, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Diabetes drug found no better than placebo at treating NAFLD
(University of California - San Diego) A diabetes medication described in some studies as an effective treatment for nonalcoholic fatty liver disease (NAFLD) works no better than a placebo, report researchers at University of California San Diego School of Medicine, after conducting the first randomized, double-blind, controlled clinical trial of sitagliptin, an oral antihyperglycemic marketed by Merck & Co. under the name Januvia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2016 Category: Global & Universal Source Type: news

Merck sales disappoint as Januvia, Remicade fall short
(Reuters) - Merck & Co Inc on Thursday reported lower-than-expected quarterly revenue, hurt by disappointing sales of its Januvia diabetes treatment and Remicade arthritis drug. (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Merck posts better-than-expected profit, raises forecast
(Reuters) - Merck & Co Inc reported better-than-expected profit in the first quarter, driven by higher sales of its diabetes drug Januvia and heart drug Zetia. (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Sitagliptin does not reduce liver fat in NAFLD
BARCELONA – Contrary to expectation, sitagliptin did not reduce liver fat in patients with early diabetes and nonalcoholic fatty liver disease in a double-blind, randomized, placebo-controlled trial.... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 30, 2016 Category: Endocrinology Source Type: news

Efficacy of Sitagliptin in Diabetes With High CVD RiskEfficacy of Sitagliptin in Diabetes With High CVD Risk
This study examines the benefits among type 2 diabetes patients at high risk for cardiovascular disease. Cardiovascular Diabetology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 27, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Gliptin Users Don't Seem to Have Higher CV Risk (CME/CE)
(MedPage Today) -- FDA pilot study contradict earlier results for Onglyza, Januvia (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 26, 2016 Category: Endocrinology Source Type: news

Two Diabetes Drugs Don't Pose Higher Heart Failure Hospitalization Risk (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD The dipeptidyl peptidase-4 (DPP-4) inhibitors saxagliptin and sitagliptin are not associated with increased risk for heart failure hospitalization relative to other diabetes … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 25, 2016 Category: Primary Care Source Type: news

No rise in serious HF seen in patients taking saxagliptin or sitagliptin
Neither saxagliptin nor sitagliptin, the two oral DPP-4 inhibitors most commonly used as antihyperglycemic medications, raised the risk of hospitalization for heart failure in a large... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 25, 2016 Category: Endocrinology Source Type: news

Diabetes drugs cleared of vascular harm
Two studies suggest that neither sulfonylureas nor sitagliptin increase the risk of adverse cardiovascular outcomes in patients with Type 2 diabetes. (Source: MedWire News)
Source: MedWire News - April 20, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news

Disappointing data for diabetes drug in the treatment of non-alcoholic fatty liver disease
(European Association for the Study of the Liver) New data presented today at The International Liver Congress™ 2016 in Barcelona, Spain, demonstrates that the drug sitagliptin - more commonly used to treat diabetes - was no more effective than placebo for reducing non-alcoholic fatty liver disease. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 16, 2016 Category: Infectious Diseases Source Type: news

Sitagliptin is 'Safest' DPP-4 Inhibitor for Type 2 DiabetesSitagliptin is 'Safest' DPP-4 Inhibitor for Type 2 Diabetes
Detailed assessment of heart-failure outcomes from TECOS study with the type 2 diabetes drug sitagliptin is published and confirms that this DPP-4 inhibitor has the safest cardiovascular profile. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 14, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

T2D patients on combination therapy benefit in switch from sitagliptin to liraglutide
BOSTON – Switching from sitagliptin to liraglutide, in combination with metformin, improved control of hypoglycemia and resulted in greater weight loss in patients with type 2 diabetes, reported Dr.... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - April 10, 2016 Category: Endocrinology Source Type: news

Merck & Co to expand in India, favourable IPR ruling encourages co to invest more
The Delhi High Court decision on its anti-diabetes drug Januvia is among the factors encouraging Merck to invest in India, global CEO Kenneth Frazier told ET. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 5, 2015 Category: Pharmaceuticals Source Type: news